CN103194460A - Preparation method of bacillus thuringiensis crystal fusion protein Bt Cry3Bb - Google Patents
Preparation method of bacillus thuringiensis crystal fusion protein Bt Cry3Bb Download PDFInfo
- Publication number
- CN103194460A CN103194460A CN2013101338434A CN201310133843A CN103194460A CN 103194460 A CN103194460 A CN 103194460A CN 2013101338434 A CN2013101338434 A CN 2013101338434A CN 201310133843 A CN201310133843 A CN 201310133843A CN 103194460 A CN103194460 A CN 103194460A
- Authority
- CN
- China
- Prior art keywords
- cry3bb
- sequence
- bacillus thuringiensis
- protein
- thuringiensis crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a preparation method of bacillus thuringiensis crystal fusion protein Bt Cry3Bb. The method relates to a gene of bacillus thuringiensis crystal protein Bt Cry3Bb, and the gene is subjected to codon optimization and is specifically shown in the sequence 1 in the sequence table. The preparation method of fusion protein Bt Cry3Bb of the bacillus thuringiensis crystal comprises the following steps of: 1) introducing a recombinant vector which contains DNA (Deoxyribonucleic Acid) fragment of the 109-2064th in the sequence 1 or in the whole sequence 1, so as to obtain recombinant escherichia coli; and 2) culturing the recombinant escherichia coli, carrying out inducible expression, collecting and splitting the thallus so as to obtain the bacillus thuringiensis crystal fusion protein Bt Cry3Bb (sequence 2). In the escherichia coli, the bacillus thuringiensis crystal protein Bt Cry3Bb gene (N-Cry3Bb gene) which is subjected to codon optimization shows that the protein activity of the obtained protein is not affected by the codon optimization.
Description
Technical field
The invention belongs to gene engineering technology field, relate to a kind of preparation method of bacillus thuringiensis crystal fusion rotein, particularly the preparation method of a kind of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb.
Background technology
Bacillus thuringiensis (Bacillus thuringiensis, be called for short Bt) in the process that forms gemma, can produce a kind of parasporal crystal, the main component of this crystal is the protein with insecticidal activity, be called as insecticidal crystal protein (ICP, Insecticidal Crystal Protein) or Bt toxalbumin.The Bt toxalbumin can be killed insects such as lepidopteran, Diptera, Coleoptera, is the biotic pesticide that are most widely used in the world at present.So far existing nearly 180 Bt toxoprotein genes are cloned and are checked order, and Cry3Bb is exactly wherein a kind of, and its main target pest is Coleoptera.
Genetically modified crops have been satisfied human demand to grain yield and economic benefit, but because foreign gene is difficult to prediction to the influence of plant physiology metabolism and genetically modified crops to the threat of environment, it utilizes and also to have risk simultaneously, and the effective way that reduces this risk is exactly that the expressed foreign protein of genetically modified crops is carried out safety evaluation.Therefore, obtain the expressed foreign protein of various Bt insecticidal crystalline genes, significant to carrying out safety evaluation, for the follow-up method of inspection is set up, the enforcement of examination criteria provides the basis, thereby can effectively prevent the generation of potential safety hazard, avoid genetically modified crops to the destruction of ecotope, give full play to the huge applications potentiality of transgenic technology in agriculture production.
Summary of the invention
An object of the present invention is to provide the gene of a kind of bacillus thuringiensis crystal protein B tCry3Bb of codon optimization.
The gene of the bacillus thuringiensis crystal protein B t Cry3Bb that described codon is optimized, be under the prerequisite that does not change bacillus thuringiensis crystal protein B t Cry3Bb aminoacid sequence (the 1-652 amino acids of GenBank:M89794.1), the codon of its wild-type encoding gene (the 202-2157 position of GenBank:M89794.1) replaced with the gene of gained behind the codon of intestinal bacteria preference (high frequency use).Be N-Cry3Bb with the unnamed gene after optimizing, specifically can be following a)-c) in arbitrary dna molecular:
A) dna molecular shown in the 109-2064 position Nucleotide of sequence 1 in the sequence table;
B) dna molecular shown in the sequence 1 in the sequence table;
C) and a) or b) dna molecular that limits has 98% identity at least, and protein DNA molecule shown in the 37-688 amino acids of encoding sequence 2 or sequence 2.
Wherein, sequence 1 is made up of 2091 Nucleotide altogether, and wherein 109-2064 position Nucleotide replaces with the gene order of gained behind the intestinal bacteria preference codon for the codon with the 202-2157 position of GenBank:M89794.1.Protein shown in the sequence 2, wherein the 37-688 amino acids of the 109-2064 position nucleotide coding sequence 2 of sequence 1 in the tabulation of sequence 1 code sequence.Sequence 2 is made up of 696 amino acid altogether.
The recombinant vectors, expression cassette, transgenic cell line or the reorganization bacterium that contain described dna molecular (N-Cry3Bb gene) also belong to protection scope of the present invention.
Described recombinant vectors can be recombinant expression vector, also can be recombinant cloning vector.
Described recombinant expression vector can be used existing expression vector establishment.Described expression vector also can comprise 3 ' end untranslated zone of foreign gene, namely comprises the dna fragmentation of polyadenylic acid signal and any other participation mRNA processing or genetic expression.The bootable polyadenylic acid of described polyadenylic acid signal joins 3 ' end of mRNA precursor.When using described gene constructed recombinant expression vector, can add any enhancement type, composing type, organizing specific type or inducible promoter before its transcription initiation Nucleotide, they can use separately or be used in combination with other promotor; In addition, when using gene constructed recombinant expression vector of the present invention, also enhanser be can use, translational enhancer or transcriptional enhancer comprised.For the ease of transgenic cell being identified and being screened, can process used expression vector, but as the gene (GFP gene, luciferase genes etc.) that adds luminophor, have the antibiotic marker thing (gentamicin marker, kantlex marker etc.) of resistance etc.
In the present invention, the promotor that the described dna molecular of startup (N-Cry3Bb gene) is transcribed in the described recombinant expression vector is specially the T7 promotor.
Described recombinant expression vector is specially described dna molecular (N-Cry3Bb gene) is inserted into the recombinant plasmid that the multiple clone site place of plasmid pET28a obtains.In one embodiment of the invention, described multiple clone site is EcoR I and XhoI.
The RNA molecule of being transcribed gained by described dna molecular (N-Cry3Bb gene) also belongs to protection scope of the present invention.
A further object of the present invention provides a kind of protein.
Protein provided by the present invention has bacillus thuringiensis crystal protein B t Cry3Bb activity, is specially the protein shown in the sequence 2 in the sequence table.
The encoding gene of described protein also belongs to protection scope of the present invention.
Described dna molecular, or described recombinant vectors, expression cassette, transgenic cell line or reorganization bacterium, or described RNA molecule, or described protein also belongs to protection scope of the present invention in the application that preparation has in the product of insecticidal activity.
In described application, described worm can be coleopteran pest; In one embodiment of the invention, described worm be specially tenebrio molitor (as 2 age tenebrio molitor).Described product can be test kit.
The application in the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb expression amount in improving intestinal bacteria of described dna molecular also belongs to protection scope of the present invention; Described bacillus thuringiensis crystal fusion rotein Bt Cry3Bb is specially protein shown in the sequence 2 in the sequence table.
Also purpose of the present invention provides the preparation method of a kind of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb.
The preparation method of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb provided by the present invention specifically comprises the steps:
1) the described recombinant vectors (as recombinant expression vector pET28a-3Bb) that will express described dna molecular imports intestinal bacteria, obtains recombination bacillus coli;
2) cultivate described recombination bacillus coli, carry out abduction delivering, collect and the cracking thalline, obtain bacillus thuringiensis crystal fusion rotein Bt Cry3Bb;
Described bacillus thuringiensis crystal fusion rotein Bt Cry3Bb is specially protein shown in the sequence 2 in the sequence table.
In aforesaid method, the described expression vector in the step 1) can be can the expressed sequence table in other recombinant prokaryotic expression vectors of dna molecular shown in the sequence 1.
In aforesaid method, step 2) in, described abduction delivering is specially: have to cultivation that to add IPTG in the nutrient solution of described recombination bacillus coli be 0.1mM to final concentration, 18 ℃ jolt and cultivated 12 hours.
It is between the 0.6-0.8 that described cultivation has the OD600 value of the nutrient solution of described recombination bacillus coli.
The rotating speed that described concussion is cultivated is 120rpm, and rotation radius is 1.5cm.
In aforesaid method, step 2) in, described " collecting and the cracking thalline " afterwards, comprise that also collect centrifugal back and the step of dissolving inclusion body.At 0.1mM IPTG, induce under 12 hours the condition for 18 ℃, described bacillus thuringiensis crystal fusion rotein Bt Cry3Bb mainly is expressed in the inclusion body.
Using gene engineering method of the present invention is synthesized bacillus thuringiensis crystal fusion rotein BtCry3Bb gene (N-Cry3Bb gene) at home first.Experiment showed, that in intestinal bacteria the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb gene (N-Cry3Bb gene) that codon provided by the present invention is optimized is expressed gained albumen not because of codon optimized its protein-active that influences.The present invention lays the foundation for detection method, physiological function and mechanism of action thereof, the degradation mechanism of further inquiring into bacillus thuringiensis crystal protein B t Cry3Bb.
Description of drawings
Fig. 1 carries out dna molecular electrophorogram behind the double digestion for recombinant plasmid with EcoR I and Xho I.Wherein, swimming lane M is that dna molecular amount standard 10Kbp is to 1000bp band (day root biotechnology (Beijing) company limited, catalog number MD100-1Kb Ladder).Swimming lane 1 carries out band behind the double digestion for recombinant expression vector pET28a-3Bb with EcoR I and Xho I.
Fig. 2 is the prokaryotic expression result (SDS-PAGE) of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb.Wherein, swimming lane M is that molecular weight of albumen standard 10KD is to 170KD band (English mill development in science and technology company limited, catalog number TF413-01 are opened up in Beijing).Swimming lane 1 changes the supernatant liquor that the control group thalline of pET28a empty carrier makes over to for cracking; Swimming lane 2 changes the supernatant liquor that the experimental group thalline of recombinant expression vector pET28a-3Bb makes over to for cracking; Swimming lane 3 changes the inclusion body that the experimental group thalline of recombinant expression vector pET28a-3Bb makes over to for cracking.The arrow indication is target protein.
Fig. 3 is the purification result (SDS-PAGE) of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb.Wherein, swimming lane M is that molecular weight of albumen standard 10KD is to 170KD band (English mill development in science and technology company limited, catalog number TF413-01 are opened up in Beijing).Swimming lane 1 is inclusion body protein coarse body fluid (solubilization of inclusion bodies liquid) before the purifying.Swimming lane 2 is inclusion body protein behind the purifying.The arrow indication is target protein.
Embodiment
Employed experimental technique is ordinary method if no special instructions among the following embodiment.
Used material, reagent etc. if no special instructions, all can obtain from commercial channels among the following embodiment.
PGOV4 cloning vector: provided by the Gene Oracle Inc. of gene Synesis Company.Be documented in " Kalle Kantola; Mohammadreza Sadeghi; Anne Lahtinen et al.Merkel cell polyomavirus DNA in tumor-free tonsillar tissues and upper respiratory tract samples:Implications for respiratory transmission and latency.Journal of Clinical Virology; 45 (2009) 292-295. " literary composition, the public can obtain from China Agricultural University.One of advantage of this carrier is to remove most conventional restriction enzyme site in its sequence, is conducive to add required site when synthetic gene, and can conflict with existing site in the sequence.In being connected of carrier and purpose fragment, not being to adopt enzyme to cut the method for connection yet, but directly connecting with concordant end.
The pET28a carrier: Novagen company, article No. is 69864-3.
Tenebrio molitor: 2 instar larvaes, Plant Protection institute, Chinese Academy of Agricultral Sciences.
Codon optimized and the full gene of embodiment 1, bacillus thuringiensis crystal protein B t Cry3Bb gene is synthetic
According to the wild-type bacillus thuringiensis crystal protein B t Cry3Bb gene order (the 202-2157 position Nucleotide of GenBank:M89794.1) in the bacillus thuringiensis (Bacillus thuringiensis), obtain being suitable for the gene order at the optimization type bacillus thuringiensis crystal protein B t of expression in escherichia coli Cry3Bb through design with verifying repeatedly, be about to wild-type bacillus thuringiensis crystal protein B t Cry3Bb gene order is transformed into intestinal bacteria preference (high frequency use) under the prerequisite that does not change aminoacid sequence (the 1-652 amino acids of GenBank:M89794.1) codon optimized sequence, thereby improve the expression level of bacillus thuringiensis crystal protein B t Cry3Bb in the intestinal bacteria culture environment.
According to aforesaid method, the final optimization type bacillus thuringiensis crystal protein B t Cry3Bb gene that obtains by the design of intestinal bacteria preference, called after N-Cry3Bb gene, its gene order are the 109-2064 position of sequence 1 in the sequence table, are made up of 1956 Nucleotide altogether.The albumen of described N-Cry3Bb genes encoding is the albumen that the 37-688 amino acids of sequence 2 in the sequence table is formed, and is identical with the albumen of the wild-type bacillus thuringiensis crystal protein B t Cry3Bb genes encoding shown in the 202-2157 position Nucleotide of GenBank:M89794.1.
The prokaryotic expression of embodiment 2, bacillus thuringiensis crystal fusion rotein Bt Cry3Bb
One, the structure of protokaryon recombinant expression vector pET28a-3Bb
Needs for construction of expression vector, the recognition sequence of restriction enzyme site EcoR I and Xho I is added at the two ends of bacillus thuringiensis crystal protein B t Cry3Bb gene (N-Cry3Bb gene) respectively after embodiment 1 gained optimization, obtains " the 103-2070 position of sequence 1 ".This sequence of synthetic, and dna fragmentation shown in this sequence linked to each other with the pGOV4 cloning vector, recombinant plasmid obtained.To show the recombinant plasmid called after pGOV4-3Bb that in the pGOV4 cloning vector, inserts dna fragmentation shown in " the 103-2070 position of sequence 1 " through order-checking.
The recombinant plasmid pGOV4-3Bb of above-mentioned structure is carried out double digestion with restriction enzyme EcoR I and Xho I, reclaim target gene fragment; The skeleton big fragment of gained target gene fragment with the pET28a carrier of cutting through same enzyme linked to each other, connect after product and change in the bacillus coli DH 5 alpha competent cell (TIANGEN Biotech (Beijing) Co., Ltd.), the coated plate screening.The picking positive monoclonal shakes bacterium, extracts plasmid, carries out double digestion with EcoR I and XhoI.Restriction enzyme mapping as shown in Figure 1.To cut evaluation through enzyme and obtain the recombinant plasmid sample presentation order-checking that size is about 5335bp and two purpose bands of 1962bp.To show between the multiple clone site EcoR of pET28a carrier I and Xho I the recombinant plasmid called after pET28a-3Bb of the 109-2064 position nucleotide sequence of sequence 1 in the insertion sequence table through order-checking.In recombinant expression vector pET28a-3Bb, all be connected with the His label that the pET28a carrier carries at the upstream and downstream of described N-Cry3Bb gene (the 109-2064 position of sequence 1), in order to carry out the purifying of target protein when carrying out prokaryotic expression; Particularly, in recombinant expression vector pET28a-3Bb, described N-Cry3Bb gene (the 109-2064 position of sequence 1) is present among the ORF shown in the whole sequence 1, and wherein the 2065-2091 position of the 1-108 position of sequence 1 and sequence 1 is the sequence that carries on the pET28a carrier.Whole sequence 1 expressed albumen is the albumen shown in the sequence 2 in the sequence table (being designated as " bacillus thuringiensis crystal fusion rotein Bt Cry3Bb ").In recombinant expression vector pET28a-3Bb, the promotor that starts described N-Cry3Bb genetic transcription is the T7 promotor.
Two, prokaryotic expression, purifying and the evaluation of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb
1, the prokaryotic expression of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb
A) the recombinant expression vector pET28a-3Bb that step 1 is obtained changes in e. coli bl21 (DE3) competent cell (TIANGEN Biotech (Beijing) Co., Ltd.) as experimental group, the e. coli bl21 (DE3) that changes empty carrier pET28a over to is set simultaneously organizes in contrast.Respectively at the LB substratum that contains 50 μ g/mL Kan, 37 ℃ of shaking culture 16h obtain culture with experimental group and control group.
B) step a) gained culture is linked in the LB substratum that contains 50 μ g/mL Kan by 1% volume, 37 ℃ of 200rpm shaking culture to bacterium liquid OD600 value between 0.6-0.8, obtain nutrient solution.
C) adding IPTG in the step b) gained nutrient solution is 0.1mM to its final concentration, and 18 ℃ jolt and cultivated 12 hours, and its rotating speed is 120rpm, and the shaking table rotation radius is 1.5cm.
D) with 4 ℃ of step c) products therefroms, the centrifugal 10min of 10000g collects thalline.
E) add BugBuster Master Mix(MERCK company in thalline, catalog number is 71456-3), consumption is the 1mg thalline: 5ml BugBuster Master Mix.60rpm shaking culture 20min obtains lysate under the room temperature.
F) with step e) gained lysate with 4 ℃, the centrifugal 20min of 12000g.On the one hand, collect supernatant; On the other hand, collecting precipitation (inclusion body), add behind the BugBuster Master Mix fully vortex (1mg precipitates corresponding 5ml lysate) in the precipitation, 4 ℃, 5000g are centrifugal, and supernatant is removed in the 10min hypsokinesis, in precipitation, add the BugBuster Master Mix diluent with 10 times of deionized water dilutions that adds 6 times of BugBuster Master Mix volumes before again, fully behind the vortex 4 ℃, 5000g centrifugal supernatant is removed in the 10min hypsokinesis, 4 ℃, the centrifugal 15min of 12000g after repeating 3 times, the supernatant that inclines obtains the high purity inclusion body; In inclusion body, add solubilization of inclusion bodies liquid (0.05M CAPS damping fluid contains 0.3%(0.3g/100mL) N-dodecyl musculamine acid sodium; The corresponding 1ml solubilization of inclusion bodies of 10mg inclusion body liquid), light and slow resuspended inclusion body; Draw supernatant behind 4 ℃, the centrifugal 20min of 12000g, obtain solubilization of inclusion bodies liquid.
Step f) gained supernatant and solubilization of inclusion bodies liquid are carried out the SDS-PAGE electrophoresis detection respectively; The SDS-PAGE method is with reference to " biochemical test method and technology " second editions of showing such as Zhang Longxiang, Higher Education Publishing House (2006), 100-106 page or leaf.Adopt 5% to concentrate glue, voltage 50V.Separation gel adopts 10% gum concentration, voltage 120V.Applied sample amount is 10 μ l.
The result as shown in Figure 2.As can be seen from the figure, compare with the control group that changes the pET28a empty carrier over to, the experimental group that changes the recombinant expression vector pET28a-3Bb that step 1 obtains over to has the purpose band to occur in the position that size is about 76KD, with consistent according to aminoacid sequence computation purpose molecular weight of albumen size in theory.In addition, it can also be seen that from the result that at 0.1mM IPTG, induce under 12 hours the condition for 18 ℃, bacillus thuringiensis crystal fusion rotein Bt Cry3Bb mainly is expressed in the inclusion body.
2, the purifying of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb
F in the above-mentioned steps 1) collected solubilization of inclusion bodies liquid is the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb that slightly carries, use BugBuster Ni-NTA His Bind purification kit (available from Novagen company, catalog number is 70751-3) and BugBuster His*Bind purification kit (available from Novagen company, catalog number is 70899-3) it is carried out purifying, the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb behind the acquisition purifying.
In the purge process, the resin that adopts BugBuster Ni-NTA His Bind test kit to provide, the purifying damping fluid that adopts BugBuster His*Bind purification kit to provide.Operate according to the method that BugBuster His*Bind purification kit provides.
3, the evaluation of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb
(1) sequence verification
Bacillus thuringiensis crystal fusion rotein Bt Cry3Bb behind the step 2 gained purifying is carried out the order-checking of N end, and the result confirms that its sequence conforms to sequence 2, has confirmed the exactness of sequence.
(2) SDS-PAGE identifies
The purification result of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb behind step 2 gained of the employing SDS-PAGE purifying is verified.With the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb(solubilization of inclusion bodies liquid of slightly carrying before the purifying) be contrast.
The SDS-PAGE method is with reference to " biochemical test method and technology " second editions of showing such as Zhang Longxiang, Higher Education Publishing House (2006), 100-106 page or leaf.Adopt 5% to concentrate glue, voltage 50V.Separation gel adopts 10% gum concentration, voltage 120V.Applied sample amount is 30 μ l.
SDS-PAGE result as shown in Figure 3.As can be seen from the figure, and compare before the purifying, the albumen purpose band behind the purifying is single, has effectively removed foreign protein.
4, the output of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb detects
Adopt BCA protein quantification test kit (BCA Protein Assay Kit, available from Novagen company, catalog number is 71285-3) the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb behind the step 2 gained purifying is carried out concentration determination, and then obtain the ultimate production of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb.The concentration determination concrete operations are carried out referring to the test kit specification sheets.3 repetitions are established in the determination of yield experiment of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb altogether, and the result gets the mean value that repeats three times.
The result shows that the output of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb is the 0.0276mg/mg thalline, and wherein " thalline " is collected bacterial sediment after the IPTG abduction delivering is cultivated.
The determination of activity of the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb that embodiment 3, embodiment 2 obtain
Get the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb that obtains among the embodiment 2, use the 0.1%(volume ratio) dilution of the Triton-100 aqueous solution, be made into 5 dilution diluents, simultaneously with the 0.1%(volume ratio) the Triton aqueous solution compares, the clean cabbage leaves that is slightly smaller than the culture dish bottom is immersed diluent to be dried after 10 seconds naturally, put into the bottom and be covered with culture dish through water-soaked filter paper, every ware insert 10 2 age Yellow meal worm larva, cultivate under the room temperature condition.The death condition of statistics Yellow meal worm larva (is touched the larva abdomen end with pen after 72 hours, if its head can not be swung, can not creep forward and then be considered as death), and utilize the LC50 value (median lethal concentration, the protein concentration of 50% Yellow meal worm larva is killed in expression) of the Yellow meal worm larva of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb that POLO computed in software embodiment 2 obtains accordingly.Each concentration arranges 4 replicate treatment groups, results averaged.
The result shows that the LC50 value of the Yellow meal worm larva of bacillus thuringiensis crystal fusion rotein Bt Cry3Bb that embodiment 2 obtains is 587.3mg/L.
Claims (10)
1.DNA molecule, for following arbitrary in a)-c):
A) dna molecular shown in the 109-2064 position Nucleotide of sequence 1 in the sequence table;
B) dna molecular shown in the sequence 1 in the sequence table;
C) and a) or b) dna molecular that limits has 98% identity at least, and protein DNA molecule shown in the 37-688 amino acids of encoding sequence 2 or sequence 2.
2. the recombinant vectors, expression cassette, transgenic cell line or the reorganization bacterium that contain the described dna molecular of claim 1.
3. recombinant vectors according to claim 2, it is characterized in that: described recombinant vectors is recombinant expression vector or recombinant cloning vector.
4. recombinant vectors according to claim 3 is characterized in that: starting the promotor that described dna molecular transcribes in the described recombinant expression vector is the T7 promotor;
Described recombinant expression vector is specially described dna molecular is inserted into the recombinant plasmid that the multiple clone site place of plasmid pET28a obtains.
5. transcribed the RNA molecule of gained by the described dna molecular of claim 1.
6. protein is the protein shown in the sequence in the sequence table 2.
7. the described dna molecular of claim 1, or arbitrary described recombinant vectors among the claim 2-4, expression cassette, transgenic cell line or reorganization bacterium, or the described RNA molecule of claim 5, or the described protein of claim 6 has application in the product of insecticidal activity in preparation.
8. the described dna molecular of claim 1 application in the bacillus thuringiensis crystal fusion rotein Bt Cry3Bb expression amount in improving intestinal bacteria; Described bacillus thuringiensis crystal fusion rotein Bt Cry3Bb is protein shown in the sequence 2 in the sequence table.
9. the preparation method of a bacillus thuringiensis crystal fusion rotein Bt Cry3Bb comprises the steps:
1) arbitrary described recombinant vectors among the claim 2-4 is imported intestinal bacteria, obtain recombination bacillus coli;
2) cultivate described recombination bacillus coli, carry out abduction delivering, collect and the cracking thalline, obtain bacillus thuringiensis crystal fusion rotein Bt Cry3Bb;
Described bacillus thuringiensis crystal fusion rotein Bt Cry3Bb is protein shown in the sequence 2 in the sequence table.
10. method according to claim 9 is characterized in that step 2) in, described abduction delivering is: have to cultivation that to add IPTG in the nutrient solution of described recombination bacillus coli be 0.1mM to final concentration, 18 ℃ jolt and cultivated 12 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310133843.4A CN103194460B (en) | 2013-04-17 | 2013-04-17 | Preparation method of bacillus thuringiensis crystal fusion protein Bt Cry3Bb |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310133843.4A CN103194460B (en) | 2013-04-17 | 2013-04-17 | Preparation method of bacillus thuringiensis crystal fusion protein Bt Cry3Bb |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103194460A true CN103194460A (en) | 2013-07-10 |
| CN103194460B CN103194460B (en) | 2015-04-08 |
Family
ID=48717278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310133843.4A Expired - Fee Related CN103194460B (en) | 2013-04-17 | 2013-04-17 | Preparation method of bacillus thuringiensis crystal fusion protein Bt Cry3Bb |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103194460B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1028510C (en) * | 1987-03-23 | 1995-05-24 | 塞里公司 | Ceramic foam filter and process for preparing same |
| CN1244697C (en) * | 2002-09-04 | 2006-03-08 | 华中农业大学 | Reforming composite insecticidal crystalline gene Cry2A of bacillus thuringiensis |
| CN100390284C (en) * | 1998-08-19 | 2008-05-28 | 孟山都技术有限公司 | Improved expression of Cry 3B insecticidal protein in plant |
| CN102010873B (en) * | 2010-11-22 | 2012-05-30 | 河南省农业科学院 | Artificially synthesized Bt insect-resistant gene Cry1Ab-t and application thereof |
| CN102586286A (en) * | 2012-03-07 | 2012-07-18 | 复旦大学 | Expression system of bacillus thur ingiens (Bt) insecticidal protein Cry1Ac-a |
| CN101492490B (en) * | 2008-01-24 | 2012-10-10 | 浙江大学 | Improved Cry3 method, improved Cry3, plasmid and uses thereof |
-
2013
- 2013-04-17 CN CN201310133843.4A patent/CN103194460B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1028510C (en) * | 1987-03-23 | 1995-05-24 | 塞里公司 | Ceramic foam filter and process for preparing same |
| CN100390284C (en) * | 1998-08-19 | 2008-05-28 | 孟山都技术有限公司 | Improved expression of Cry 3B insecticidal protein in plant |
| CN1244697C (en) * | 2002-09-04 | 2006-03-08 | 华中农业大学 | Reforming composite insecticidal crystalline gene Cry2A of bacillus thuringiensis |
| CN101492490B (en) * | 2008-01-24 | 2012-10-10 | 浙江大学 | Improved Cry3 method, improved Cry3, plasmid and uses thereof |
| CN102010873B (en) * | 2010-11-22 | 2012-05-30 | 河南省农业科学院 | Artificially synthesized Bt insect-resistant gene Cry1Ab-t and application thereof |
| CN102586286A (en) * | 2012-03-07 | 2012-07-18 | 复旦大学 | Expression system of bacillus thur ingiens (Bt) insecticidal protein Cry1Ac-a |
Non-Patent Citations (4)
| Title |
|---|
| DONOVAN,W.P.: "M89794.1", 《GENBANK》, 26 April 1993 (1993-04-26), pages 1 - 2 * |
| RINA IANNACONE 等: "Specific sequence modifications of a cry3B endotoxin gene result in high levels of expression and insect resistance", 《PLANT MOLECULAR BIOLOGY》, vol. 34, no. 3, 30 June 1997 (1997-06-30), pages 485 - 496 * |
| 田颖川 等: "人工合成素云金芽孢杆菌杀虫蛋白基因cry1A（C）在大肠杆菌中的表达及对烟草的转化", 《农业生物技术学报》, vol. 3, no. 2, 30 April 1995 (1995-04-30), pages 45 - 52 * |
| 高洁荣 等: "苏云金芽孢杆菌Cry2Aa蛋白的体外表达及纯化", 《湖北农业科学》, vol. 52, no. 3, 28 February 2013 (2013-02-28), pages 702 - 703 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103194460B (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Proteomic analysis of interaction between a plant virus and its vector insect reveals new functions of hemipteran cuticular protein | |
| Bi et al. | A typical C-type lectin, perlucin-like protein, is involved in the innate immune defense of whiteleg shrimp Litopenaeus vannamei | |
| Liu et al. | Cry64Ba and Cry64Ca, two ETX/MTX2-type Bacillus thuringiensis insecticidal proteins active against hemipteran pests | |
| CN104387460B (en) | A kind of insecticidal proteins of water resistant brown plant-hopper and its encoding gene and application | |
| Cheng et al. | Gene-to-gene network analysis of the mediation of plant innate immunity by the eliciting plant response-like 1 (Epl1) elicitor of Trichoderma formosa | |
| Huang et al. | HcCUB-Lec, a newly identified C-type lectin that contains a distinct CUB domain and participates in the immune defense of the triangle sail mussel Hyriopsis cumingii | |
| Zhang et al. | Identification and characterization of Hyphantria cunea aminopeptidase N as a binding protein of Bacillus thuringiensis Cry1Ab35 toxin | |
| Wang et al. | Venom of the parasitoid wasp Pteromalus puparum contains an odorant binding protein | |
| Odintsova et al. | Defensins of grasses: A systematic review | |
| Feng et al. | Domain III of Bacillus thuringiensis Cry1Ie toxin plays an important role in binding to peritrophic membrane of Asian corn borer | |
| Tian et al. | Sustaining induced heat shock protein 70 confers biological thermotolerance in a high‐temperature adapted predatory mite Neoseiulus barkeri (Hughes) | |
| Han et al. | Novel fibrinogen-related protein with single FReD contributes to the innate immunity of Macrobrachium rosenbergii | |
| Wang et al. | An LCI‐like protein APC2 protects ginseng root from Fusarium solani infection | |
| CN101418039B (en) | Novel antibacterial peptide and preparation method and use thereof | |
| Luo et al. | The characterization of SaPIN2b, a plant trichome-localized proteinase inhibitor from Solanum americanum | |
| Yao et al. | ABCC2 is a functional receptor of Bacillus thuringiensis Cry1Ca in Spodoptera litura | |
| Zhang et al. | Functional conservation and division of two single-carbohydrate-recognition domain C-type lectins from the nipa palm hispid beetle Octodonta nipae (Maulik) | |
| Ren et al. | LvCPG2 facilitated WSSV infection by interaction with VP26 and VP28 | |
| Huang et al. | Molecular characterization of two toll receptors in hyriopsis cumingii and their potential roles in antibacterial response | |
| CN104311648A (en) | Insecticidal protein as well as coded gene and application of insecticidal protein | |
| Zhou et al. | Construction of silkworm midgut cDNA library for screen and sequence analysis of peritrophic membrane protein genes | |
| Sun et al. | Gene expression patterns in response to pathogen challenge and interaction with hemolin suggest that the Yippee protein of Antheraea pernyi is involved in the innate immune response | |
| CN103194460B (en) | Preparation method of bacillus thuringiensis crystal fusion protein Bt Cry3Bb | |
| Liu et al. | Identification, annotation of Mucin genes in channel catfish (Ictalurus punctatus) and their expression after bacterial infections revealed by RNA‐Seq analysis | |
| CN103233022B (en) | Preparation method of bacillus thuringiensis crystal fusion protein Bt Cry9C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150408 Termination date: 20170417 |